Search results
Results From The WOW.Com Content Network
Pegylated interferon alfa-2a, sold under the brand name Pegasys among others, is medication used to treat hepatitis C and hepatitis B. [3] For hepatitis C it is typically used together with ribavirin and cure rates are between 24 and 92%.
Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat multiple sclerosis. [ 4 ] [ 5 ] The most common side effects include headache, muscle pain, joint pain, influenza (flu)-like symptoms, pyrexia (fever), chills, asthenia (weakness), and erythema (reddening of the skin), pain or pruritus (itching) at the ...
A 2013 meta-analysis over Clinical Infectious Diseases noted the combination-treatment to be safe as well as effective for children and adolescents; other meta-analyses had noted the same for adult population. [9] A 2012 meta-analysis had found PEGylated interferon alfa-2a to be the more effective variant for treatment-naive patients. [10]
In the United States, as of 2015, the cost is between US$1,284 and US$1,386 per 30 mcg vial. [31] As of 2020, the National Average Drug Acquisition Cost (NADAC) in the United States for Avonex was $6,872.94 for a 30 mcg kit. [32] Avonex and Rebif are on the top ten best-selling multiple sclerosis drugs of 2013. [33]
Biogen Idec Submits Application to FDA for Approval of PLEGRIDY™ (Peginterferon Beta-1a) in Multiple Sclerosis — EMA Submission Planned in the Coming Weeks — WESTON, Mass.--(BUSINESS WIRE ...
Peginterferon-alfa may refer to: Peginterferon alfa-2a , an antiviral drug used in treatment for hepatitis C and hepatitis B Peginterferon alfa-2b , a treatment for hepatitis C
Pegylated interferon (PEG-IFN) is a class of medication that includes three different drugs as of 2012: [1]. Pegylated interferon-alpha-2a; Pegylated interferon-alpha-2b ...
[3] [6] Ropeginterferon alfa-2b is the first medication approved by the US Food and Drug Administration (FDA) to treat polycythemia vera that people can take regardless of their treatment history, and the first interferon therapy specifically approved for polycythemia vera. [3] The FDA considers it to be a first-in-class medication. [7]